Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Agenus Inc (NQ: AGEN )

3.160 USD -0.235 (-6.92%)
Official Closing Price Updated: 7:50 PM EST, Mar 4, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about Agenus Inc

< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Recently Released Market Study: GSK's MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
New York, NY -- (SBWIRE) -- 09/05/2013 -- Agenus Inc., (NASDAQ:AGEN) a developer of treatments for cancer and infectious diseases, plummeted the most in four years after partner GlaxoSmithKline Plc’s... 
From SBWire - Latest Press Releases
Hot Stock: Antigenics, Shares Drop 33.2% (AGEN)
From Comtex SmarTrend® News Briefs
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) and Agenus Inc. (NASDAQ:AGEN) Added to Equity Profile Report's NASDAQ Decliners Watch List.
Wilmington, DE -- (SBWIRE) -- 09/05/2013 -- Equity Profile Report expands its NASDAQ Decliners Weekly Watch List adding Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) and Agenus Inc.... 
From SBWire - Latest Press Releases
Higher Open As Jobless Claims Fall
First time applications for unemployment benefits fell to a five year low to lift the markets to a higher open with the Dow gaining 30 points to 14,960. Nasdaq rose 10 points to 3659. 
Tags Market News
From MarketMinute.com Market Updates
Antigenics: The Losing Streak Continues (AGEN)
From Comtex SmarTrend® News Briefs
Morning Market Losers
Agenus (NASDAQ: AGEN ) dropped 32.35% to $2.51. Agenus shares have dropped 25.20% over the past 52 weeks, while the S&P 500 index has gained 15.43% in the same period. Bazaarvoice (NASDAQ: BV )... 
Tags US6065011040 News CONN
From Benzinga
Higher Open As Jobless Claims Fall
Tags Market Updates CONN KDN
From MarketMinute » Market Updates
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
From Business Wire News Releases
Agenus to Present at Two Upcoming Healthcare Conferences
From Business Wire News Releases
Traders Get Bullish on Shares of Antigenics, Shares Up 7.9% (AGEN)
From Comtex SmarTrend® News Briefs
Agenus Reports Second Quarter 2013 Financial Results
Agenus to Host Conference Call Beginning at 11 a.m. ET Today 
From GlobeNewswire News Releases
Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013
From Business Wire News Releases
Hot Stock: Antigenics, Shares Gain 5.2% (AGEN)
From Comtex SmarTrend® News Briefs
Agenus to Report Second Quarter 2013 Financial Results on July 25, 2013; Conference Call to Follow
From GlobeNewswire News Releases
Agenus to Present at the JMP Securities Annual Healthcare Conference
From GlobeNewswire News Releases
Agenus to Webcast Annual Shareholders' Meeting
From GlobeNewswire News Releases
Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors
Study Seeking to Enroll 222 Patients; Largest Vaccine Trial Ever Funded by NCI in Brain Tumors and the Largest Cancer Vaccine Study Ever Conducted in Combination With Avastin 
From GlobeNewswire News Releases
1 Stock to Buy, 1 Stock to Short: Small-Cap Pharma
 
Tags NASDAQ:PPHM NASDAQ:AGEN
From InvestorPlace
Mentor Capital Cancer Immunotherapy Index Gains 28% During First Quarter of 2013
From Business Wire News Releases
Positive Phase 2 Data from Agenus' Brain Cancer Vaccine Presented at Plenary Session of American Academy of Neurological Surgeons Meeting
Newly Diagnosed Patients With Brain Tumors Treated With Prophage Vaccine Show Improvement in Progression Free Survival and Overall Survival Compared to Standard of Care 
From GlobeNewswire News Releases
Agenus Reports First Quarter 2013 Financial Results
Agenus to Host Conference Call Beginning at 11 a.m. ET Today 
From GlobeNewswire News Releases
Agenus to Report First Quarter 2013 Financial Results on April 24, 2013; Conference Call to Follow
From GlobeNewswire News Releases
Agenus Eliminates Its $39 Million Senior Notes and Completes $10 Million of New Debt Financing
From GlobeNewswire News Releases
Agenus' Brain Cancer Vaccine Results to be Presented at Plenary Session of the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting
First Phase 2 Data From Prophage G-100 (HSPPC-96) Newly Diagnosed Glioma Program 
From GlobeNewswire News Releases
Notable Microcap Stocks: Manning and Napier Inc, Reed's, Affymax, Agenus Inc
Lakeway, TX -- (SBWIRE) -- 03/19/2013 -- Bestdamnpennystocks, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the... 
From SBWire - Latest Press Releases
Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013
From Business Wire News Releases
Agenus to Present at the ROTH Annual Conference
From GlobeNewswire News Releases
UPDATE: Dawson James Reiterates Agenus Inc. at Buy After Rapid Phase II Trial Enrollment on HerbV
In a report published by Dawson James, analyst Robert M. Wasserman reiterated a Buy rating and $6.00 price target on Agenus, Inc. (NASDAQ: AGEN ) Dawson James reported that, “Key developments for the... 
Tags Analyst Color Dawson James AGEN
From Benzinga
NW Bio Provides Guidance On Phase III Trial Enrollment Timing: Completion Expected To Be Faster Or More Efficient Than Relevant Comparison Trials
From PR Newswire
Agenus Reports Fourth Quarter and Year End 2012 Financial Results
Agenus to Host Conference Call Beginning at 11 a.m. ET Today 
From GlobeNewswire News Releases
< Previous 1 2
...
24 25 26 27 28 29 30 31 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.